BioCentury
ARTICLE | Clinical News

ASF-1057: Phase IIb start

October 30, 2006 8:00 AM UTC

By year end, Astion will begin a double-blind, placebo-controlled, French Phase IIb trial (Study 205) in 60 patients. Subjects will receive 1 of 2 doses of ASF-1057 or placebo twice-daily for 3 weeks....